Warby Parker Inc (WRBY)vsWest Pharmaceutical Services Inc (WST)
WRBY
Warby Parker Inc
$23.38
+1.39%
HEALTHCARE · Cap: $2.86B
WST
West Pharmaceutical Services Inc
$247.02
+0.71%
HEALTHCARE · Cap: $17.68B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 253% more annual revenue ($3.07B vs $871.90M). WRBY leads profitability with a 19.0% profit margin vs 16.1%. WST trades at a lower P/E of 36.1x. WST earns a higher WallStSmart Score of 55/100 (C-).
WRBY
Avoid34
out of 100
Grade: F
WST
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-31314.3%
Fair Value
$0.07
Current Price
$23.38
$23.31 premium
Margin of Safety
-256.8%
Fair Value
$68.99
Current Price
$247.02
$178.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 46 in profit
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.6%
Areas to Watch
0.0% earnings growth
Weak financial health signals
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
2.1% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : WRBY
The strongest argument for WRBY centers on Return on Equity. Profitability is solid with margins at 19.0% and operating margin at -4.5%. Revenue growth of 11.2% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.
Bear Case : WRBY
The primary concerns for WRBY are EPS Growth, Piotroski F-Score, P/E Ratio. A P/E of 2338.0x leaves little room for execution misses.
Bear Case : WST
The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
WRBY carries more volatility with a beta of 2.06 — expect wider price swings.
WRBY is growing revenue faster at 11.2% — sustainability is the question.
WST generates stronger free cash flow (175M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WST scores higher overall (55/100 vs 34/100), backed by strong 16.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. is an innovative leader in the direct-to-consumer eyewear market, redefining the optical landscape since its founding in 2010. By seamlessly blending a robust online platform with a growing number of physical retail outlets, the company enhances customer engagement while maintaining a focus on stylish, affordable prescription eyewear and sunglasses. Warby Parker's commitment to social impact is exemplified by its "Buy a Pair, Give a Pair" initiative, which fosters community support by providing eyewear to those in need. With a unique brand identity and forward-thinking marketing strategies, Warby Parker is well-positioned for continued expansion and enduring success in the competitive eyewear industry.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?